Joel Schneider
Chief Executive Officer at Carbon Biosciences, Inc.
Joel Schneider active positions
| Companies | Position | Start | End |
|---|---|---|---|
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Chief Executive Officer | - | - |
| President | - | - |
Career history of Joel Schneider
Former positions of Joel Schneider
| Companies | Position | Start | End |
|---|---|---|---|
| SOLID BIOSCIENCES INC. | Director/Board Member | 28/02/2015 | 31/12/2016 |
| Chief Operating Officer | 01/03/2021 | 26/05/2022 | |
| Chief Tech/Sci/R&D Officer | 31/12/2016 | 01/03/2021 | |
| Corporate Officer/Principal | 28/02/2014 | 28/02/2015 |
Training of Joel Schneider
| Brandeis University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| Private companies | 1 |
|---|---|
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
- Stock Market
- Insiders
- Joel Schneider
- Experience
